After producing an in situ DC vaccine (HELA–Exos) by loading the immunogenic cell death inducers human neutrophil elastase and Hiltonol into alpha-lactalbumin (α–LA)-loaded breast cancer exosomes, the authors were able to introduce a potential target therapy for breast cancer (see Table 1). Here, ELANE is linked to breast carcinoma.